144 ·Filed May 13, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001972481-26-000156
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, small-dollar insider sale by a director following RSU vesting. No material signal for traders. Monitor for any larger insider sales ahead of upcoming clinical catalysts or earnings.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
DYN ▲ +44.97% at T+60d
NEUTRAL call ✓ call won +44.97% · α vs SPY +41.38% · entry $18.28 → $26.50
Entry anchored
May 13, 2026
via day open
T+1d
-5.42%
call -5.42% · α -4.19%
$17.29
settled 5mo ago
T+5d
-4.98%
call -4.98% · α -4.26%
$17.37
settled 5mo ago
T+20d
-0.49%
call -0.49% · α +0.37%
$18.19
settled 4mo ago
T+60d
+44.97%
call +44.97% · α +41.38%
$26.50
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Director John Cox filed a Form 144 notice of intent to sell 3,311 shares of Dyne Therapeutics common stock, valued at approximately $60,805 based on the filing date. This is a small, routine sale by a director, representing a negligible fraction of the company's $3.0B market cap, and is not indicative of material insider concern.

Key Facts

  • Director John Cox filed Form 144 to sell 3,311 shares of DYN common stock.
  • Estimated sale value: ~$60,805 based on filing date.
  • Shares are from restricted stock units that vested on 05/12/2026.
  • Sale represents a tiny fraction of DYN's $3.0B market cap.
  • Recent insider activity (30d): 9 sells totaling $5.0M, indicating some ongoing insider selling but not unusual for a biotech.

Financial Impact

~$60,805 sale by a director, immaterial relative to $3.0B market cap

dilution

Risk Factors

  • Insider selling pattern may increase if more directors file 144s ahead of data readouts.
  • Biotech sector risk: any negative clinical data could amplify insider selling concerns.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001972481-26-000156
Document: 0001972481-26-000156-index.html0001972481-26-000156
Document: 0001972481-26-000156.txt0001972481-26-000156
44 reports for DYN
Performance horizon
87% Hit rate 13 of 15 directional calls best @ T+60▲ +46.36%May 20, 2026
Filters
Rows
Reports for DYN — sortable, filterable
TypeNow
Aug 17, 2026
6w ago
Insider Cluster
BEARISH ★ 6/10
$26.15 $17.90▲ +31.55%▲ +29.57%$15.20 (+41.87%)
Aug 14, 2026
6w ago
144
NEUTRAL ★ 4/10
$26.15 $18.52▼ −29.18%▼ −27.65%$15.20 (−41.87%)
Aug 13, 2026
7w ago
144
BEARISH ★ 6/10
$25.70 $18.52▲ +27.94%▲ +25.95%$15.20 (+40.86%)
Aug 13, 2026
7w ago
144
NEUTRAL ★ 2/10
$25.70 $18.52▼ −27.94%▼ −25.95%$15.20 (−40.86%)
Aug 13, 2026
7w ago
144
NEUTRAL ★ 2/10
$25.70 $18.52▼ −27.94%▼ −25.95%$15.20 (−40.86%)
Jul 29, 2026
9w ago
Press Release
BULLISH ★ 7/10
$25.73 $26.09▲ +1.40%▼ −2.57%$15.20 (−40.92%)
Jul 22, 2026
10w ago
Press Release
BEARISH ★ 6/10
$23.21 $26.78▼ −15.38%▼ −12.48%$15.20 (+34.51%)
Jul 20, 2026
10w ago
8-K
BULLISH ★ 7/10
$23.45 $26.15▲ +11.51%▲ +7.39%$15.20 (−35.18%)
Jun 30, 2026
13w ago
Insider Cluster
NEUTRAL ★ 5/10
$21.79 $25.10▲ +15.19%▲ +17.38%$15.20 (−30.24%)
Jun 29, 2026
13w ago
144
BEARISH ★ 4/10
$22.21 $25.63▼ −15.40%▼ −16.43%$15.20 (+31.56%)
Showing 10 of 44

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access